NCT00238316View on ClinicalTrials.gov

Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 5, 2000

Primary Completion Date

November 16, 2007

Study Completion Date

February 10, 2009

Conditions
Breast Cancer
Interventions
DRUG

letrozole

2.5 mg PO daily for 1 year

OTHER

Placebo

2.5 mg PO daily for one 1 year

Trial Locations (10)

02114

Massachusetts General Hospital Cancer Center, Boston

02115-6084

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

T2N 4N2

Tom Baker Cancer Centre - Calgary, Calgary

B3H 1V7

Nova Scotia Cancer Centre, Halifax

L8N 1Y2

Hamilton Osteoporosis Diagnostic Services, Hamilton

K1H 8L6

Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa

L2R 5K3

St. Catharines General Hospital at Niagara Health System, St. Catharines

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre at Sunnybrook Health Sciences Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

H2W 1T8

Hotel Dieu de Montreal, Montreal

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK

NCT00238316 - Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density | Biotech Hunter | Biotech Hunter